This review discusses the evolution, challenges, and innovations of antibody-drug conjugates (ADCs) in cancer treatment. It focuses on the importance of precise target selection and engineering to improve efficacy while minimizing off-target toxicities. Recent advances such as pH-dependent antibodies, dual-epitope targeting, and AI-guided profiling are highlighted as promising strategies to enhance safety and therapeutic impact.

Newly developed DNA nanostructures can form flexible, fluid, and stimuli-responsive condensates without relying on chemical cross-linking, report researchers from Institute of Science Tokyo and Chuo University. Owing to a rigid tetrahedral motif that binds the linkers in a specific direction, the resulting string-like structures form condensates with exceptional fluidity and stability. These findings pave the way for adaptive soft materials with potential applications in drug delivery, artificial organelles, and bioengineering platforms.

A joint research team led by Dr. Sung Jong Yoo at the Center for Hydrogen and Fuel Cells of the Korea Institute of Science and Technology (KIST, President Sang-Rok Oh), Professor Dong Won Chun of POSTECH, Professor Yongsoo Yang of KAIST, and Professor Haneul Jin of Dongguk University has developed a new catalyst technology that enables the synthesis of highly active and durable catalyst at room temperature using a simple ultrasound-assisted method.